Category Oncology

Viewing 1–10 of 38

Show

Sort

  1. Professions: Physician
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OT0219
    Published: February 2019
    Expires: 1/31/2021
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Richard Simoneaux
    Categories: Diagnostic Studies , Gynecological , Oncology
    Specialties: Gynecology, Hematology, Oncology, Radiology
    Topics: Germline BRCA Mutation , Talazoparib in Advanced Breast Cancer

  2. Professions: Other Health Professional
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OTN0219
    Published: February 2019
    Expires: 1/31/2021
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Richard Simoneaux
    Categories: Diagnostic Studies , Gynecological , Oncology
    Specialties: Gynecology, Hematology, Oncology, Radiology
    Topics: Germline BRCA Mutation , Talazoparib in Advanced Breast Cancer

  3. Professions: Physician
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OT0119
    Published: January 2019
    Expires: 12/31/2020
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Richard Simoneaux
    Categories: Oncology , Pediatrics
    Specialties: Hematology, Radiology
    Topics: Children , Leukemia , Radiation Exposure

  4. Professions: Other Health Professional
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OTN0119
    Published: January 2019
    Expires: 12/31/2020
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Richard Simoneaux
    Categories: Oncology , Pediatrics
    Specialties: Hematology, Radiology
    Topics: Children , Leukemia , Radiation Exposure

  5. Professions: Physician
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OT1218
    Published: Dec 2018
    Expires: 12/31/2020
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Richard Simoneaux
    Categories: Oncology
    Specialties: Oncology
    Topics: Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC

  6. Professions: Other Health Professional
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OTN1218
    Published: Dec 2018
    Expires: 12/31/2020
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Richard Simoneaux
    Categories: Oncology
    Specialties: Oncology
    Topics: Lenvatinib vs. Sorafenib as First-Line Treatment for Unresectable HCC

  7. Professions: Physician
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OT1118
    Published: Nov 2018
    Expires: 10/31/2020
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Richard Simoneaux
    Categories: Oncology
    Specialties: Oncology
    Topics: A TKI in Activating Anticancer Innate Immunity

  8. Professions: Other Health Professional
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OTN1118
    Published: Nov 2018
    Expires: 10/31/2020
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Richard Simoneaux
    Categories: Oncology
    Specialties: Oncology
    Topics: A TKI in Activating Anticancer Innate Immunity

  9. Professions: Physician
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OT1018
    Published: Oct 2018
    Expires: 9/30/2020
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Jacqueline S. Garcia, MD; Matthew S. Davids, MD, MMSc
    Categories: Oncology
    Specialties: Oncology
    Topics: New Treatments for Relapsed Hematologic Malignancies After alloHCT

  10. Professions: Other Health Professional
    Price: $10.00

    Credits:

    • ACCME 1.0 CME
    Planner
    Test Code: OTN1018
    Published: Oct 2018
    Expires: 9/30/2020
    Sources: Oncology Times
    Passing Score: 7/10 (70%)
    Authors: Jacqueline S. Garcia, MD; Matthew S. Davids, MD, MMSc
    Categories: Oncology
    Specialties: Oncology
    Topics: New Treatments for Relapsed Hematologic Malignancies After alloHCT

Viewing 1–10 of 38